Aerosol Medicine

Efficient inhalation systems are crucial for the successful treatment of serious lung diseases and the development of new therapies.

Chronic respiratory diseases are suffered by 10-20% of the population worldwide and it is predicted that in 2020 chronic obstructive pulmonary disease (COPD) will be the second leading cause of death. Inhalation of drug aerosols is the best way to treat these diseases effectively. This form of therapy deposits the drug directly to the lungs thereby providing a targeted local treatment. This approach will improve the efficiency and will prevent the systemic exposure of active drug ingredients to other organs in the body.

Since patients with severe lung diseases inhale their medication during constantly fluctuating and sub-optimal breathing, the biggest challenge of inhalation therapy is to get a sufficient dose of drug deposited in the lung. For these reasons conventional inhalation systems only reach a deposition rate in the lung of 5-15% - a major concern especially when administering expensive drugs.

In this specialist field of inhalation therapy Activaero is an international leader of controlled inhalation technology. Activaero invented FAVORITE - Flow and Volume Regulated inhalation Technology. A key feature of this technology is that it enables patients breathing to be controlled electronically thereby adjusting the individual's lung function so that it always mimics optimal breathing.

Integrating this technology into Activaero's AKITA^® inhalation systems enables drug deposition into the lungs to be greatly improved. Deposition in the lungs reaches up to 80% of the drug dose prescribed by Activaero's devices. FAVORITE inhalation ensures that every patient receives the same dose. This is an important benefit for long-term treatment of chronic lung diseases and particularly for clinical trials of new drugs. In this area Activaero is expecting a significant appreciation value for the own technology. The goal for future programs is to deliver well-known medications to the lungs using the AKITA^® inhalation system and in turn, develop and market new therapeutic advances.